INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 120 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2017. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,149,957 | -16.0% | 137,262 | +2.1% | 0.01% | -20.0% |
| Q2 2023 | $8,513,563 | +122432.6% | 134,453 | +4.8% | 0.01% | +11.1% |
| Q1 2023 | $6,948 | +2.6% | 128,317 | +0.3% | 0.01% | 0.0% |
| Q4 2022 | $6,771 | -99.9% | 127,947 | +4.9% | 0.01% | +12.5% |
| Q3 2022 | $5,678,000 | -11.4% | 122,028 | +8.7% | 0.01% | -11.1% |
| Q2 2022 | $6,409,000 | +19.2% | 112,286 | +27.8% | 0.01% | +28.6% |
| Q1 2022 | $5,377,000 | +34.8% | 87,882 | +15.3% | 0.01% | +40.0% |
| Q4 2021 | $3,990,000 | +38.6% | 76,239 | -1.2% | 0.01% | +25.0% |
| Q3 2021 | $2,878,000 | -4.5% | 77,196 | +4.5% | 0.00% | 0.0% |
| Q2 2021 | $3,015,000 | -5.5% | 73,866 | -21.4% | 0.00% | 0.0% |
| Q1 2021 | $3,190,000 | -1.3% | 94,026 | -7.5% | 0.00% | 0.0% |
| Q4 2020 | $3,232,000 | +40.8% | 101,643 | +13.6% | 0.00% | 0.0% |
| Q3 2020 | $2,295,000 | -11.3% | 89,454 | -11.2% | 0.00% | 0.0% |
| Q2 2020 | $2,586,000 | +104.4% | 100,757 | +22.5% | 0.00% | +33.3% |
| Q1 2020 | $1,265,000 | -46.1% | 82,281 | +20.4% | 0.00% | -25.0% |
| Q4 2019 | $2,345,000 | +366.2% | 68,361 | +1.5% | 0.00% | +300.0% |
| Q3 2019 | $503,000 | -39.1% | 67,344 | +5.9% | 0.00% | -50.0% |
| Q2 2019 | $826,000 | +12.4% | 63,604 | +5.4% | 0.00% | +100.0% |
| Q1 2019 | $735,000 | +6.1% | 60,366 | -0.8% | 0.00% | -50.0% |
| Q4 2018 | $693,000 | -24.7% | 60,872 | +43.6% | 0.00% | 0.0% |
| Q3 2018 | $920,000 | +0.9% | 42,391 | -17.8% | 0.00% | 0.0% |
| Q2 2018 | $912,000 | +1.2% | 51,596 | +20.5% | 0.00% | 0.0% |
| Q1 2018 | $901,000 | +44.2% | 42,816 | -0.9% | 0.00% | +100.0% |
| Q4 2017 | $625,000 | -9.3% | 43,187 | -1.1% | 0.00% | 0.0% |
| Q3 2017 | $689,000 | +28.1% | 43,676 | +0.9% | 0.00% | 0.0% |
| Q2 2017 | $538,000 | -20.9% | 43,296 | +3.5% | 0.00% | -50.0% |
| Q1 2017 | $680,000 | +11.5% | 41,841 | +3.6% | 0.00% | 0.0% |
| Q4 2016 | $610,000 | +3.9% | 40,396 | +5.0% | 0.00% | 0.0% |
| Q3 2016 | $587,000 | -54.6% | 38,488 | +15.6% | 0.00% | -50.0% |
| Q2 2016 | $1,292,000 | +77.5% | 33,281 | +27.1% | 0.00% | +100.0% |
| Q1 2016 | $728,000 | -46.9% | 26,183 | +2.7% | 0.00% | -50.0% |
| Q4 2015 | $1,372,000 | +78.9% | 25,503 | +33.1% | 0.00% | +33.3% |
| Q3 2015 | $767,000 | +30.0% | 19,158 | +3.8% | 0.00% | +50.0% |
| Q2 2015 | $590,000 | +65.3% | 18,455 | +23.4% | 0.00% | +100.0% |
| Q1 2015 | $357,000 | +66.0% | 14,955 | +23.0% | 0.00% | 0.0% |
| Q4 2014 | $215,000 | +33.5% | 12,155 | +3.6% | 0.00% | – |
| Q3 2014 | $161,000 | -18.7% | 11,730 | 0.0% | 0.00% | -100.0% |
| Q2 2014 | $198,000 | – | 11,730 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |